Background
==========

Epidemiological research in acute respiratory distress syndrome (ARDS) is important to understand the variability in disease presentations, patterns of care, and outcome in different patient populations.^[@bib1]^ Limited data is available regarding the epidemiological and clinical profile of ARDS patients in Middle Eastern countries.

ARDS is a common cause of admission to critical care units. It causes significant morbidity and still carries high mortality.^[@bib2]--[@bib4]^ A specialized data registry system ensures the uniformity of diagnostic criteria and the detailed documentation of studied variables. Registry data is informative in the study of differences in etiological factors, population characteristics, patterns of clinical care, and resource utilization in different populations. The incidence, clinical course, morbidity, and outcome of ARDS in medical patients have not been previously studied in Qatar, a country that is mostly composed of a multinational expatriate population. Furthermore, the introduction of extracorporeal membrane oxygenation (ECMO) service in 2014 provided a unique perspective of studying the utility of this modality in ARDS management.

Materials and Methods
=====================

This investigation was a retrospective observational study utilizing the medical intensive care unit (MICU) one-year (2015) registry data at the main tertiary hospital in Qatar. The institution\'s Medical Research Center approved this study.

Inclusion criteria
------------------

All ARDS patients aged \>14 years admitted to MICU during the study period.

Diagnosis of ARDS was based on the Berlin definition for ARDS,^[@bib2]^ which includes the following:- Onset over one week or less- Bilateral opacities consistent with pulmonary edema on computed tomography scan or chest radiograph- PF ratio \< 300 mm Hg with a minimum of 5 cm H~2~O positive end-expiratory pressure (PEEP), or continuous positive airway pressure (CPAP)- Above conditions are not fully explained by cardiac failure or fluid overload

Exclusion criteria
------------------

• Patients with respiratory failure who did not fulfill ARDS criteria• Patients aged ≤ 14 years• Surgical or trauma patients who were not admitted to MICUData were collected using a data collection form and included patients\' age, gender, nationality, past major illness (diabetes mellitus, immunosuppression, chronic kidney, liver, pulmonary and heart diseases), clinical disorders precipitating ARDS, length of intensive care stay, mechanical ventilation days, and ICU outcome. Blood biochemistry, arterial blood gases, hematocrit, total leukocyte count, platelet count, blood cultures, procalcitonin levels, chest radiograph, and other variables were noted. The clinical and biochemical variables collected were noted within the first 24 hours of the diagnosis of ARDS and the Acute Physiology and Chronic Health Evaluation (APACHE II) scores were calculated from the above data. The relevant clinical data of the subjects were collected until discharge from the hospital or death. The final diagnosis and outcome were recorded.

Suspected bacterial infections were diagnosed on the basis of increased inflammatory marker levels and procalcitonin levels of \>2.0 ng/mL and confirmed if bacterial cultures were positive. Viral infections were confirmed using viral panel polymerase chain reaction or suspected if procalcitonin levels were low and other causes of ARDS were excluded.

Complications associated with ICU stay that were recorded included circulatory support with vasoactive agents, acute renal failure requiring dialysis, central line-associated bloodstream infections (CLABSI), pneumothoraces, and ventilator-associated pneumonia (VAP).

Results of the study are presented to show the epidemiological and clinical profiles of survivors and nonsurvivors admitted to MICU with the diagnosis of ARDS.

Statistical analysis: The data is presented as the total number of patients, mean ± SD for continuous variables, and percentage for categorical variables. Statistical analysis was performed using Student\'s t-test and chi-square test as appropriate. A *p* value \< 0.05 was considered to be statistically significant.

Results
=======

In 2015, a total of 682 patients were admitted to MICU. Of those, 101 (14.8%) patients met the Berlin diagnostic criteria for ARDS. Differences in epidemiological and clinical variables between survivors and nonsurvivors are presented in [Table 1](#tbl1){ref-type="table"}.

With regard to demographic data, local Qatari patients were older (mean age, 49.95 ± 21.67 years) than expatriates (mean age, 42.54 ± 15.30 years) (*p* = 0.05).

The overall survival rate was 65% (n = 66). Mortality was significantly higher with increasing mean age, higher APACHE II score, higher procalcitonin levels, higher requirement of vasopressors for circulatory support, lower PO~2~/FIO~2~ ratio, higher Murray\'s score, higher PCO~2~, lower pH, and development of VAP. There was no statistically significant difference in mortality in relation to comorbidities, mode of mechanical ventilation, need for dialysis, ECMO support, and CLABSI.

The overall mean tidal volume (TV) prescribed was 386.86 ± 62.36 ml, which was higher than the 362.31 ± 58.69 ml that was calculated based on ideal body weight (*p = *0.0002). Eleven (11%) patients had a tracheostomy.

The total length of stay for ARDS patients was 17.8 ± 13.6 days, which was significantly higher than the total length of stay of 10.1 ± 11.5 days for the population admitted to MICU (*p* \< 0.001).

The causes of ARDS and mortality outcome are shown in [Table 2](#tbl2){ref-type="table"}. Community-acquired bacterial and viral pneumonia were responsible for ARDS in around 69% of all cases. Only 10 (10%) trauma patients with ARDS were admitted to MICU, as they required management for severe respiratory failure with ECMO support.

Approximately 27% of patients required ECMO support ([Table 3](#tbl3){ref-type="table"}). Patients with viral pneumonia and trauma had better chances of survival on ECMO than those with other etiologies.

Discussion
==========

Epidemiological registries in ARDS provide valuable sources of information that can improve understanding of the disease, patterns of care, and variables affecting outcome.^[@bib1]^ The current study focused on single-year (2015) data when specific data collection for auditing was planned, and cases were tracked from admission to discharge.

In the current study, 14.8% of all ICU admissions were for ARDS, which is consistent with other published data where incidence varies from 2.5% to 19%.^[@bib3]--[@bib5]^

A male predominance of 72% in our study is consistent with that reported in other international studies^[@bib6]^ and is also explained by the overall composition of the Qatari population, which has a disproportionally higher number of males.^[@bib7]^ This predominance may represent disproportionally higher risk factors for ARDS development in males than in females. The relatively young mean age in our study population is likely explained by the presence of a population of young expatriate workers in the country. Similar to the results of other studies, older age was associated with a higher mortality rate.^[@bib8]^

In our study, the crude mortality rate of ARDS patients was 35%, which is not different from that reported in other studies.^[@bib2],[@bib3]^ This result was predicted by a significantly higher APACHE II score of 28.54 ± 6.98 in nonsurvivors compared with an APACHE II score of 17.26 ± 5.93 in survivors.

Diabetes mellitus, immunosuppression, chronic pulmonary, cardiac, and liver diseases are the comorbidities that were assessed in our study ([Table 1](#tbl1){ref-type="table"}). There was no statistically significant difference in the outcome of ARDS patients with risk factors and comorbidities when compared with those without any risk factors or comorbidities. On the other hand, as shown in other studies,^[@bib9]^ increasing mean age, higher APACHE II severity score, lower P/F ratio, higher Murray\'s score, higher PCO~2~, lower pH, higher procalcitonin levels, and VAP, were significantly associated with increased crude mortality.^[@bib10]^

Both the mode of ventilation and higher PEEP were not associated with any mortality benefit in this study. Overall, mean TV was higher than that calculated by the predicted body weight. This has been observed in other studies as well. This observation emphasizes the need to review local data to confirm that there is no disconnect between the theoretical and practical application of evidence-based practices in the ICU.^[@bib11]^ Although the prone position is a standard therapy for severe ARDS with mortality benefits,^[@bib12]^ it was performed in only 8% of the cases in 2015. This was likely because of inadequate training and experience of the team in the use of prone position for ARDS in 2015. This highlights the crucial role of education, training, and experience of the respiratory failure care team members in the use of the prone position in ARDS patients. After this observation, multiple educational workshops have been conducted for all ICU team members, and the prone position has become a standard step in the management of appropriate ARDS patients.

The predominant cause for admission in our study was community-acquired pneumonia in 69% of patients. Patients with community-acquired viral pneumonia had an overall survival rate of 85%, which is similar to 75% survival with ECMO reported in another study.^[@bib13]^

Although case series have reported ECMO use as salvage therapy for acute respiratory failure in pulmonary tuberculosis (TB),^[@bib14],[@bib15]^ three of our patients who required ECMO as a lifesaving salvage therapy did not survive. This may represent more advanced underlying pulmonary TB in our study. Large-scale studies of pulmonary TB cases with salvage ECMO may better define the role of ECMO in this patient population.

Ten (10%) patients with ARDS secondary to trauma were admitted to the ECMO service in MICU. Four out of the seven (57%) patients requiring ECMO survived. The overall survival reported in other studies for venovenous (VV) ECMO in acute respiratory failure in trauma patients ranges from 50% to 79%.^[@bib16]^

Our study showed that the overall intensive care outcome in VV ECMO in severe ARDS at our center was 44% in 2015, and the Extracorporeal Life Support Organization international report indicates a survival rate of 57% in the corresponding year.^[@bib17]^

This study emphasizes the utility of registry data at an individual center to compare the practice with international standards.

The benefits of this objective data also help evaluate practices that otherwise may not be obvious. This was apparent in our objective data of TV use, which was higher than recommended. Also, prone position data helped us improve our overall practice in this area. Registry data is also useful in securing more resources from local leadership with a relatively major impact on patient care improvement. The limitation of this study is that being a descriptive retrospective study, where part of the data is collected from the medical records, the significance of the observed differences between various clinical variables among survivors and nonsurvivors could not be assessed. The study did not specifically explore the variability among ARDS secondary to different etiologies. Also, the registry data was limited to ICU stay, and no medium or long-term outcome after ICU discharge was evaluated.

Conclusion
==========

Specific ARDS registries provide valuable information on the epidemiology of the disease; factors that affect the outcome; and adherence to standardized, evidence-based care. In our center, bacterial and viral pneumonia remain the dominant etiologies of ARDS. The outcome of ARDS patients is primarily influenced by the etiology and severity of the disease. Despite the well-recognized importance of low TV strategy and prone position in ARDS, the mean TV used was higher than recommended, and the utilization of prone position remains low. Local data exploration by adopting registries is a useful way to explore the regional differences in ARDS epidemiology and routine clinical care, which may help improve overall outcomes in ARDS patients. This study demonstrates ARDS as an important healthcare problem in Qatar, which requires healthcare authorities to develop preventive strategies and advance its management.
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###### 

Epidemiological and clinical variables in survivors versus nonsurvivors.

                                       All (n = 101)    Survivors (n = 66)   Nonsurvivors (n = 35)   *p* value
  ------------------------------------ ---------------- -------------------- ----------------------- -----------
  Mean age (years ± SD)                44.96 ± 17.97    42.09 ± 13.58        50.36 ± 16.84           0.008
                                                                                                     
  Gender (n)                                                                                         0.981
                                                                                                     
   Male                                72               47                   25                      
                                                                                                     
   Female                              29               19                   10                      
                                                                                                     
  Nationality (n)                                                                                    0.277
                                                                                                     
   Local                               33               24                   9                       
                                                                                                     
   Expatriates                         68               42                   26                      
                                                                                                     
  Comorbidities                                                                                      
                                                                                                     
   Diabetes mellitus                   35               23                   12                      0.954
                                                                                                     
   Chronic heart disease               8                5                    3                       0.860
                                                                                                     
   Chronic lung disease                13               9                    4                       0.752
                                                                                                     
   Immunosuppression                   9                6                    3                       0.930
                                                                                                     
   Chronic liver disease               6                2                    4                       0.089
                                                                                                     
  APACHE II                            21.17 ± 7.32     17.26 ± 5.93         28.54 ± 6.98            0.0001
                                                                                                     
  P/F ratio                            97.83 ± 35.19    103.57 ± 34.28       86.86 ± 33.56           0.021
                                                                                                     
  Murray\'s score                      3.22 ± 0.43      3.149 ± 0.42         3.34 ± 0.53             0.049
                                                                                                     
  PCO~2~                               50.65 ± 13.40    46.57 ± 10.61        58.56 ± 19.34           0.0001
                                                                                                     
  pH                                   7.24 ± 0.12      7.29 ± 0.20          7.14 ± 0.15             0.0001
                                                                                                     
  Procalcitonin                        40.08 ± 48.19    28.30 ± 34.3         64.42 ± 75.56           0.001
                                                                                                     
  Noninvasive ventilation (n)          20               15                   5                       0.311
                                                                                                     
  Prone (n)                            8                4                    4                       0.342
                                                                                                     
  Mode of mechanical ventilation (n)                                                                 0.311
                                                                                                     
   VAC                                 78               53                   25                      
                                                                                                     
   PAC                                 23               13                   10                      
                                                                                                     
  Tidal volume (ml)                    386.86 ± 62.36   396.85 ± 47.63       368.39 ± 46.25          0.004
                                                                                                     
  PEEP                                 12.4 ± 2.75      12.08 ± 2.48         13 ± 3.21               0.113
                                                                                                     
  Mechanical ventilation days          14.71 ± 11.75    11.61 ± 7.0          20.2 ± 20.76            0.003
                                                                                                     
  Mean length of stay (days)           17.75 ± 13.56    15.53 ± 9.19         21.94 ± 22.37           0.045
                                                                                                     
  Dialysis (n)                         29               12                   17                      0.103
                                                                                                     
  ECMO (n)                             27               12                   15                      0.095
                                                                                                     
  CLABSI (n)                           2                1                    1                       0.066
                                                                                                     
  VAP (n)                              8                2                    6                       0.013
                                                                                                     
  Pneumothorax (n)                     4                2                    2                       0.645
                                                                                                     
  Circulatory support (n)              81               49                   32                      0.039
                                                                                                     

###### 

Etiology of ARDS.

  Etiology                            All (n = 101)   Survivors (n = 66)   Nonsurvivors (n = 35)
  ----------------------------------- --------------- -------------------- -----------------------
  Viral pneumonia                     33              28 (85.0%)           5 (15.0%)
                                                                           
  CAP bacterial                       36              23 (64%)             13 (36.0%)
                                                                           
  Hospital-acquired pneumonia         6               2 (33.0%)            4 (67.0%)
                                                                           
  Aspiration pneumonia                5               1 (20%)              4 (80.0%)
                                                                           
  Tuberculosis                        3               0                    3 (100.0%)
                                                                           
  Malaria                             1               1 (100%)             0
                                                                           
  *Pneumocystis jiroveci* pneumonia   1               1 (100%)             0
                                                                           
  Extrapulmonary sepsis               5               2 (40%)              3 (60.0%)
                                                                           
  Alveolar hemorrhage                 1               1 (100%)             0
                                                                           
  Trauma                              10              7 (70.0%)            3 (30.0%)
                                                                           

###### 

ECMO indications and outcome.

  Etiology                          ECMO   Survival on ECMO
  --------------------------------- ------ ------------------
  Viral pneumonia                   8      6
                                           
  CAP bacterial                     6      1
                                           
  Aspiration pneumonia              1      0
                                           
  Tuberculosis                      3      0
                                           
  Pneumocystis Jiroveci pneumonia   1      1
                                           
  Extrapulmonary sepsis             1      0
                                           
  Trauma                            7      4
                                           
  Total                             27     12
                                           
